Anthony J. Japour - 09 Jan 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Reporting relationship: Director
Issuer ticker: COCP
Reported as of: 09 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2026, 16:10:03 UTC
Prior SEC filing: 11 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Anthony Japour

Key filing fact

Anthony J. Japour filed Form 4 for Cocrystal Pharma, Inc. (COCP) on 13 Jan 2026.

Key facts

This page summarizes Anthony J. Japour's Form 4 filing for Cocrystal Pharma, Inc. (COCP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jan 2026, 16:10.

Change

Previous filing in this sequence was filed on 11 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001773088 Primary reporting owner

Japour Anthony J

Relationship: Director
Address: 19805 N. CREEK PARKWAY, BOTHELL
Signature: /s/ Anthony Japour
Signature date: 13 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +16,410
Change %
Price: $0.000000
Shares after: 16,410
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,410
Exercise price: $1.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.